A

Actinium Pharmaceuticals
D

ATNM

1.17000
USD
-0.05
(-4.10%)
مغلق
حجم التداول
1,415
الربح لكل سهم
-1
العائد الربحي
-
P/E
-1
حجم السوق
36,499,192
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    ABBV
    ABBV
    1.200
    (0.60%)
    202.140 USD
    AMGN
    AMGN
    5.10
    (1.71%)
    303.15 USD
    BMY
    BMY
    0.050
    (0.09%)
    55.840 USD
    GSK
    GSK
    -0.320
    (-0.87%)
    36.650 USD
    JNJ
    JNJ
    2.680
    (1.68%)
    162.370 USD
    MRK
    MRK
    1.820
    (2.08%)
    89.500 USD
    PFE
    PFE
    0.405
    (1.56%)
    26.305 USD
    المزيد
الأخبار
المقالات

العنوان: Actinium Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.